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ABSTRACT 
 
 
As the global burden of liver disease evolves, a need for noninvasive detection 
and diagnosis has emerged. For over fifty years biopsy has been the standard to 
which all other disease detection and confirmation methods have been 
compared. With the development of several noninvasive methods in the 
detection of liver disease, biopsy has come under scrutiny for its cost-
effectiveness, reliability and safety. Serologic testing has proven useful but not 
specific overall for the determination of disease stages. Liver stiffness is a 
relatively new parameter used in the diagnosis and monitoring of hepatic 
disease.  It is a quantifiable through the use of an ultrasound-based method of 
transient elastography using a tool Fibroscan. The implementation of transient 
elastography has changed the paradigm of liver disease diagnostics with a more 
cost effective, reproducible, reliable, and well-tolerated option.  
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While the hepatitis C virus is the primary cause of fibrosis and cirrhosis, 
numerous studies of the application of liver stiffness measurement to varying 
disease etiologies have broadened the scope of the method. Optimizing reliability 
criteria has been the focus of many studies to find a standard by which cirrhosis 
may be ruled out and fibrosis staging may be accomplished. Novel non-interferon 
based HCV therapies are altering the course of disease progression and may 
affect the need for continued development of noninvasive monitoring procedures. 
However, globally the impact of advanced liver disease is rising with an increase 
in mortality by fifty million cases per year from 1990-2010 indicating the 
continued relevance and need for widely applicable noninvasive procedures for 
both diagnosing hepatic disease and informing treatment options.  
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INTRODUCTION 
 
The accurate detection, diagnosis, and treatment of hepatic disease is becoming 
increasingly important globally. Total mortality worldwide from cirrhosis and 
hepatocellular carcinomas rose by fifty million per year over the span of two 
decades according to the first-ever World Health Organization (WHO) study of 
liver disease mortality conducted from 1990 to 2010 [36]. Advanced liver disease 
is now considered a substantial contributor to global mortality with the incidence 
of both cirrhosis and liver cancer on the rise. In the United States alone chronic 
hepatitis C (CHC) infection is a major etiology of hepatic disease and as such is 
a growing public health concern making detection essential for prognoses and 
treatment decisions. According the WHO report published in 2012, Hepatitis C 
was the primary cause of both liver cancer and cirrhosis in 2010, accounting for 
41% and 40% of cases respectively. Comorbities and coinfections with hepatic 
disease are also becoming more prevalent. One such example is coinfection with 
human immunodeficiency virus (HIV). Since the first decade of the widespread 
use of highly active antiretroviral (HAART) therapies the course of HIV infection 
has been dramatically altered and mortality reduced. As a result of this shift, liver 
disease has emerged as a leading cause of morbidity and mortality among HIV 
patients who are dually infected with the hepatitis C virus (HCV) [37]. What 
develops out of these statistics and information is the clear need for a method of 
early detection and diagnosis which fits within the restrictions of the current 
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insurance system as well as the parameters of clinical settings here in the United 
States but with the potential for global applications.   
 
All chronic liver diseases whether of toxic, genetic, autoimmune, or viral origin 
cause the organ to undergo typical histological changes that ultimately lead to 
fibrosis, cirrhosis, and the excess deposition of extracellular matrix [21]. Liver 
fibrosis is the result of the healing of parenchymal injury in chronic liver diseases 
and, left uninterrupted, this process will result in liver cirrhosis and its various 
complications. The extent of the scarring and hardening of hepatic tissue due to 
the wound response process is a good prognostic measure for individuals with 
liver disease. Assessing the stages of fibrosis accurately is essential for 
informing the course of treatment as well as monitoring disease progression. 
Many techniques have been explored and used over more than fifty years to 
allow for early and reliable detection of fibrosis but these previous care standards 
are limited in their utility and practicality for ongoing assessment. Invasive 
procedures lead to greater risk of infection and complications as well as longer 
patient recovery times, increased costs, and decreased likelihood of patient 
compliance with serial monitoring.  
 
 
3 
 
Biopsy 
For approximately fifty years, biopsy has been the gold standard of evaluation 
and histological diagnosis for liver fibrosis and cirrhosis. The clinical value of a 
biopsy is procuring a live sample from which disease gradation and staging can 
be histologically determined. Grading reflects necroinflammatory activity and 
integrates lesion severity while staging reflects the extent of fibrosis (Fig.1, 2). 
Information about liver disease can be assessed and determined through biopsy, 
leading to its primary role among diagnostic methods. The METAVIR scoring 
scale for fibrosis and cirrhosis allows pathologists to grade fibrotic activity as: F0-
F4, no fibrosis and cirrhosis respectively with F1, 2, 3 representing intermediate 
levels of fibrosis. Despite universal use, the biopsy procedure has significant 
drawbacks and risks. On a practical level, biopsy is expensive, requiring hospital 
admission and the use of a specialized room, instruments, and a team of medical 
staff. It is, therefore, far from an ideal procedure to repeat often for continuous 
disease monitoring. Interobserver variation in histological interpretation makes a 
diagnosis based on biopsy less objectively reliable when there is disagreement 
between pathologists. While this is a rare occurrence, it is still a consideration, 
particularly when diagnosing intermediate stages when there are fewer 
histological distinctions in the organ tissue.  As with any invasive procedure, a 
risk exists, Sharma et al. found a mortality rate of 0.01% and rate of 
complications of 0.3% in their 2014 review of noninvasive diagnostic methods [31]. 
Another factor that limits the utility of biopsy is acquiring the specimen itself, or 
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sampling error. A satisfactory tissue sample is typically 10-15 mm in length and 
1.0-1.4 mm in diameter containing four to six portal tracks. A sample this size 
represents approximately 1/50,000 of the entire liver and is often not 
representative of the disease state of the organ as a whole. Accurate 
determination of intermediate stages is a particular limitation which cannot 
always be overcome by optimal sample size. Diagnoses of F0 and F4 are 
typically more reliable due to more representative and less ambiguous 
histological patterns. Even with the chance of an accurate diagnosis, patients are 
often unwilling to undergo repeated biopsies due to invasiveness and recovery 
time. These limitations have led to the need to develop noninvasive and cost-
effective procedures which either maintain or improve upon the diagnostic 
accuracy of biopsy. 
 
Table 1: METAVIR Fibrosis Stages 
METAVIR Score Stage Description 
F0 none no fibrosis 
F1 moderate 
fibrosis 
portal fibrosis  
without septa 
F2 significant  
fibrosis  
portal fibrosis 
with few septa 
F3 severe  
fibrosis 
numerous septa 
without cirrhosis 
F4 cirrhosis cirrhosis 
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Table 2: Necrosis Stages 
Necrosis Stage Description 
0 no inflammation 
1 peri-portal inflammation no hepatocellular necrosis 
2 inflammation with mild hepatitis 
3 severe portal inflammation with moderate hepatitis 
4 marked inflammation with severe hepatitis 
 
Table 3: Hepatitis Stages 
Hepatitis Stage Description 
A compensated 
B beginning to decompensate 
C decompensated  
 
Disease Indicators & Diagnostic Methods 
As with any pathology, liver disease has numerous clinically relevant markers 
and indicators. The development of tools which assess the presence or indeed 
absence of these markers has been vital in the evolution of accurate diagnostics 
and appropriate treatment regimens. Hepatic disease diagnostic methods can be 
broken down into categories and subcategories (Fig. 1) [21]. Invasive methods 
include laparoscopy, endoscopy, and biopsy which until recently has been the 
standard for liver disease detection and diagnosis. Laparoscopic and endoscopic 
procedures are not particularly sensitive in their ability to identify disease 
indicators in vivo. Noninvasive methods can be radiologic or serologic in nature. 
Radiologic and imaging methods include magnetic resonance imaging (MRI), 
ultrasound (US), computer tomography (CT), and elastography. Conventional 
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imaging via US, MRI, and CT while noninvasive, is not sensitive to the explicit 
signs of cirrhosis such as the genesis of new blood vessels called collaterals and 
the nodular surface of the organ ultimately limiting the utility of these three 
methods. Serum-based disease biomarkers can be broadly classified as either 
direct or indirect. Direct methods assess extracellular matrix turnover and hepatic 
fibrogenesis. Liver function decline is indirectly assessed via the presence of 
various enzymes in blood and serum samples. Radiologic and serum-based 
markers of fibrosis correlate well with biopsy scores, especially when used to 
exclude the presence of fibrosis and cirrhosis, a clinically useful feature which 
can often allow for biopsy to be avoided [30]. 
 
Figure 1: Invasive and noninvasive methods to determine liver fibrosis, adapted 
from Meuller & Sandrin, 2010 [21] 
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Fibrotest®, APRI, and Other Serologic Assessments 
An ideal serologic diagnostic test would be specific for hepatic tissue, easy to 
execute, and perform independently of concurrent inflammatory and fibrotic 
processes. The biomarkers assessed with these ideal tests would be freely 
available within the serum, independent of an inflammatory response, not 
influenced by secretion, and correlated with the process of fibrogenesis [31]. This 
list of requirements breaks down into identifying a factor that can: 1. be assessed 
independently of others present in the serum, i.e. one that is not bound to or 
influenced by another molecule, 2. one whose circulating levels do not increase 
when acute inflammation occurs, 3. a factor which is not a component of ongoing 
metabolic processes and eliminated by the liver, 4. a biomarker which is involved 
in the wound healing process that results in the deposition of new liver tissue. 
Serum markers categorized as indirect reflect changes in hepatic function, i.e. 
platelet count, coagulation factors, and serum transaminases. Direct markers of 
fibrosis indicate matrix turnover and consist of synthesis and degradation 
enzymes, collagen deposition factors, and several proteinases [31]. There are 
three major second generation panel tests which provide diagnostic information 
regarding fibrosis stage; these are FibroTest, Hapascore, and FibrometerA [7]. 
These panel tests have the specificity to discriminate between mild and clinically 
significant fibrosis as well as advanced fibrosis and cirrhosis. Out of the three 
second generation serologic tests, Fibrotest is the most used and widely studied. 
Chrostek et al. and Shaheen et al. discuss the utility and accuracy of Fibrotest 
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and its application to various disease etiologies [7, 29]. The Fibrotest is a 
composite of five serum biomarkers: α-2-macroglobulin, apolipoprotein A1, 
hatopglobin, γ-glutamyltranspeptidase, and bilirubin. Chrostek et al. indicated in 
their 2014 study that Fibrotest had a 100% negative predictive value (NPV) for 
the absence of significant fibrosis and a greater than 90% positive predictive 
value (PPV) for significant fibrosis [7]. These findings indicate that Fibrotest is 
highly sensitive because the test ruled out fibrosis in 100% of the cases in which 
patients did not have significant fibrosis and resulted in a positive reading in 90% 
of cases in which patients did have significant fibrosis [7]. In the Shaheen et al. 
review of nine studies assessing Fibrotest, they compared the sensitivities and 
specificities of the test’s diagnostic thresholds and determined that studies with 
an increased prevalence of advanced fibrosis reported improved test 
performance [2]. Therefore, while it is sensitive, Fibrotest is not adequately 
specific and limited in its ability to distinguish lower and intermediate grades of 
fibrosis. 
 
Aspartate aminotransferase to platelet ratio index (APRI) is another noninvasive 
and readily available tool and has been widely studied due to its universal 
applicability and simplicity. Compared to other serum panel tests, APRI is a 
single measure which evaluates the level of the circulating blood enzyme 
aspartate aminotransferase (AST). AST is an enzyme associated with the 
9 
 
parenchymal or functional cells of the liver and is typically measured as part of a 
liver function test. When measured as a ratio with platelet cells, it is an indicator 
of cellular turnover and breakdown. In a 2013 meta-analysis by Chou et al. which 
Sharma et al. referenced in their 2014 review, APRI was shown to have 55% 
specificity and 81% sensitivity for the diagnosis of fibrosis in hepatitis C patients 
across the 28 studies included in the analysis [31]. Toniutto et al aimed to 
determine the usefulness of this test in their 2007 study to detect fibrosis in 
transplant patients with recurrent HCV [35].  They found an overall sensitivity of 
0.76, specificity of 0.77, PPV of 46%, and a NPV of 93% among their study 
population indicating that APRI is a good method for ruling out the presence of 
fibrosis (Table 4) [35].  While useful for its NPV and lower cost, APRI accuracy has 
not been established for a broader range of etiologies and its diagnostic value is 
lower than some other serum biomarkers.    
 
Table 4: APRI Parameters, data from Toniutto et al, 2007 [35] 
Characteristic All Patients (n=102) 
Sensitivity 0.76 (0.58-0.89) 
Specificity 0.77 (0.72-0.80) 
PPV 0.46 (0.35-0.53) 
NPV 0.93 (0.87-0.97) 
 
A newer development is a panel which detects serum mircoRNAs as potential 
biomarkers of nonalcoholic fatty liver disease (NAFLD). MicroRNAs are a class of 
non-coding, highly conserved RNAs that control post-transcriptional gene 
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expression. As such they are linked to cellular differentiation, development, 
metabolism, proliferation, and apoptosis. They have more recently been found to 
regulate a spectrum of liver functions [34]. A pilot study using a serum microRNA 
panel to diagnose NAFLD by Tan et al. indicated an increased sensitivity of 
diagnostic accuracy compared to other biomarkers for NAFLD [34]. While more 
research on a larger scale is needed, this method of diagnosis may prove 
promising specifically for NAFLD diagnosis. However, it is not universally 
applicable to all etiologies of hepatic disease thus limiting its utility.  
 
Although serologic markers reflect profibrogenic activity, they do not always 
correlate directly with the absolute amount of matrix deposited, limiting their 
diagnostic utility [21]. Serum-based testing is a valuable tool in a clinical setting 
but may be insufficient to make a complete diagnostic determination due to 
specificity limitations. Used as an initial and less expensive starting point, 
serologic testing has the ability to determine the presence or absence of fibrosis 
but not the specific stage. Overall, serum markers for fibrosis correlate well with 
the two extremes of the METAVIR scale and clinically these types of 
assessments may eliminate some need for more invasive procedures but they do 
not represent a replacement for biopsy. Continued research into the 
pathophysiology of fibrosis and cirrhosis may identify new markers and 
encourage the development of diverse serum testing. 
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Liver Stiffness  
Liver stiffness (LS) is a relatively new parameter used in the diagnosis and 
monitoring of hepatic disease.  It is quantifiable through the use of an ultrasound-
based method of transient elastography using a tool called Fibroscan. The 
stiffness of the liver changes over time with the progression of fibrosis and is 
therefore an observable and qualifiable measure of disease state and functions 
as a particularly reliable surrogate marker for advanced fibrosis and cirrhosis. LS 
is expressed in kilopascals (kPa) and is a measurement that is dependent on 
many factors: the extracellular matrix of the liver, the constraints applied on the 
organ, the internal pressure of the organ, and the viscous effects over the time 
constant that the liver is subjected to during testing [21]. Liver stiffness 
measurement (LSM) is ideal for serial monitoring of disease progression over 
time and carries fewer of the risks and a fraction of the cost of the previous 
clinical standard. Mueller and Sandrin presented the range of kPA values which 
correlate to fibrotic stage in their 2010 review of liver stiffness as a novel 
parameter in the ongoing search for noninvasive methods of diagnosing hepatic 
diseases (Table 5, Figure 2) [20].  Considerations in accurately assessing liver 
stiffness include whether the patient is undergoing alcohol detoxification causing 
hepatocellular swelling, experiencing an acute inflammation flare related to liver 
disease, or undergoing tumor infiltration as all these scenarios can lead to over 
estimation of LS and result in an inaccurate categorization of fibrosis stage. 
Figure 2 also indicates other conditions which affect liver stiffness which alter 
12 
 
LSM but do not affect fibrosis stage. Controlling for these circumstances, LSM is 
a more global representation of the condition of the organ than biopsy. The latter 
method only assesses a small sample of tissue which may not give a full 
diagnostic picture. The goal of novel diagnostic techniques is to improve early 
detection of and thus inform appropriate treatment. Additional applications of 
LSM would be earlier recognition of fibrosis and cirrhosis-related complications 
such as portal hypertension, esophageal varices, liver cancers, as well as 
monitoring response to treatment.  
 
Table 5: Liver Stiffness Range, adapted from Mueller & Sandrin, 2010 [21] 
Stiffness kPa Fibrosis 
soft <6 normal, F0 
intermediate 6-8 intermediate F1/2 
moderate 8-12.5 fibrosis, F3 
stiff >12.5 cirrhosis, F4 
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Figure 2: Pressure Associated Conditions, taken from Mueller & Sandrin, 2010 
[21] 
 
TRANSIENT ELASTOGRAPHY  
Elastography and Fibroscan® 
The development of elastographic techniques yielded four major categories: 
static elastography, dynamic elastography, transient elastography, and remote 
elastography [25]. Some of these methods are limited by high sensitivity, boundary 
conditions of the tissue tested (i.e. external forces that exert pressure), 
acquisition times, compatibility with specific organs, and prohibitive costs. 
Transient elastography (TE) differs from other ultrasound-based techniques by 
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the kind of mechanical stimulation it relies upon. The use of transient vibration 
offers advantages over other methods: 1. the transmitted elastic wave can be 
temporally separated from the reflected waves thereby making the method less 
sensitive to eternal forces that affect the stiffness of the tissue tested; 2. 
acquisition time is short enabling measurements to be conducted on moving 
organs making the technique well-adapted to the study of the liver. Fibroscan 
(Figure 3) [25], which uses transient elastography technology (TE), is a tool for 
liver stiffness evaluation (LSE) capable of assessing soft biological tissue 
stiffness in vivo.  
 
 
Figure 3: The Fibroscan®, taken from Sandrin et al, 2003 [25] 
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To perform a liver stiffness measurement as shown in Figure 4 [9], the Fibroscan 
probe is positioned at the intercostal space on the right side of a patient who is 
laying in the dorsal decubitus position with their right arm in maximal abduction 
(i.e. lying on the back with the right arm behind the head) to access the right lobe 
of the liver which contains the region of interest (ROI). A typical ROI in a LSE is 
often about 100 times larger than a biopsy sample. An additional advantage of 
TE is that a single ultrasonic transducer can be used as a low frequency vibration 
generator, emitter, and receiver. The transducer probe generates vibrations of a 
low frequency, typically 50Hz, which are transmitted through liver tissue resulting 
in a shear wave propagating through the ROI at a particular velocity. The probe 
uses pulse-echo ultrasound (US) to then follow the propagation of the initial wave 
to measure its velocity which determines liver stiffness (LS). This is possible to 
achieve with one probe because of the aforementioned temporal separation of 
transmitted and reflected waves. Liver elasticity is determined from the velocity of 
the low frequency shear wave which propagates through the ROI tissue. The 
slope of the shear wave pattern depicted in Figure 5 increases with advanced 
fibrosis grade [25]. As fibrosis spreads through the liver in worsening disease 
states, tissue elasticity decreases resulting in a faster propagation velocity of 
shear waves through the organ which corresponds to a steeper slope. Therefore, 
more advanced disease means a stiffer liver and an elevated LSM calculated in 
kPa [25]. 
16 
 
 
 
Figure 4: Schematic of a transient elastography system, taken from Cournane, 
Browne, and Fagan, 2012 [9] 
 
 
Figure 5: Elastic wave propagation in liver with different fibrotic stages, adapted 
from Sandrin et al, 2003 [25] 
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Fibroscan Studies 
The METAVIR fibrosis scale of F0-F4, a staging scale used to categorize biopsy 
results, remains the standard to which noninvasive method measurements are 
compared and correlates to Fibroscan cutoff values (Table 6) [30]. Liver stiffness 
measured by TE is indicative of the level of fibrosis and disease state and is 
measured in kilopascals (kPa). Numerous studies have developed cut off values 
which correspond to each stage and those numbers varied depending on 
disease etiology. In 2014, Sharma et al. published a prospective study to 
determine the usefulness of Fibroscan in the evaluation of liver fibrosis [30]. Their 
objective was to find a correlation between liver stiffness measurement (LSM) 
and the fibrosis stage assessed by liver biopsy (LB) and determine predictors of 
discordance between the two methods. A secondary goal was to find similar 
correlation between aspartate transaminase to platelet ratio index (APRI) and LB 
outcomes. Both the METAVIR classification system and AUROC values were 
used to evaluate TE and APRI accuracy in 185 patients who underwent both LB 
and TE. Fibrosis stages were graded by two blinded and independent 
pathologists. After eliminating some participants due to unreliable TE readings or 
inadequate biopsy results, the sample was reduced to 175 patients. A significant 
difference was noted in the LSM values for patients with F0 compared to mild 
fibrosis of F1-2 and advanced fibrosis of F3-4. The AUROC for significant 
fibrosis, i.e. F>2, was 0.98 with an optimal TE cutoff value of ≥10.0 pKa. The 
sensitivity and specificity at this cutoff were 98% and 89% respectively. The 
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optimized cutoff value to predict cirrhosis was determined at ≥14.7 pKa with a 
sensitivity of 97% and a specificity of 96%. Elevated bilirubin of >10.5 mg/dL was 
an independent predictor of a false TE reading. A median APRI value for patients 
without fibrosis was 0.47, with a significant difference between no fibrosis and 
mild fibrosis. The difference in the APRI value between mild and advanced 
fibrosis was also statistically significant. In comparing the two noninvasive 
methods the AUROC as well as sensitivity and specificity for TE are greater than 
those same parameters calculated for APRI. Thus the researchers determined 
that LSM is a reliable predictor of hepatic fibrosis and is, in fact, superior to APRI 
for noninvasive diagnosis of fibrosis and cirrhosis [30].  
 
Table 6: Correlation between METAVIR and FS Values, data from Sharma et al, 
2014 [30] 
METAVIR 
score 
FS Values 
(kPa) 
Fibrosis Stage 
F0 ≤4.5 no fibrosis 
F1 7.5 fibrosis without septa 
F2 ≥10 fibrosis with few septa 
F3 ≥12.5 numerous septa without cirrhosis 
F4 ≥14.7 cirrhosis  
 
In their systematic review of diagnostic test accuracy for hepatitis C-related 
fibrosis published in 2007, Shaheen, Wan, and Meyers discussed how accurate 
diagnosis is crucial for determining disease prognosis and making treatment 
decisions. As hepatitis C is the primary cause of advanced liver disease 
worldwide and affected 3.2 million Americans at the time of their study, the 
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researchers functioned within the framework that standard interferon-ribavirin 
therapies only resulted in sustained virologic response in 50-60% of patients with 
only a minority of HCV patients having access or eligibility for treatment [29]. A 
priority for clinical research is the development of accurate staging methods in 
order to estimate prognosis an inform treatment. In this study the three 
researchers compared Fibroscan to biopsy as well as other noninvasive 
diagnostic methods with their primary outcome as the differentiation of mild from 
moderate fibrosis, i.e. F0-1 from F2-3. This outcome was chosen because the 
point of antiviral therapy indication is usually when a patient transitions into the 
moderate stage. Specifically for cutoffs of 7.1-8.8 kPa, Fibroscan had summary 
sensitivity and specificity of 64% and 87% respectively. The secondary outcome 
was the identification of cirrhosis, F4. The researchers found Fibroscan has 
improved accuracy for this outcome compared to biopsy, with a sensitivity of 86% 
specificity of 93% for LS threshold of 12.5-14.8 kPa [29]. 
 
Table 7: Specificity and Sensitivity of Fibroscan, data from Shaheen, Wan, & 
Meyers, 2007 [29] 
Fibrosis Stage pKa Threshold Sensitivity  
AUC (95% CI) 
Specificity  
AUC(95% CI) 
Moderate 7.1-8.8 0.64 (0.5-0.76) 0.87 (0.8-0.91) 
Cirrhosis  12.5-14.8 0.86 (0.78-0.91) 0.93 (0.9-0.95) 
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LSM Reliability Criteria & Cutoff Value Optimization 
Over time investigators have continued to determine appropriate and optimized 
cut off values for the measurements that correlate both with LSM reliability and 
accuracy of determining fibrotic stages. Accurate positive and negative predictive 
values are an important aspect of this work. Positive predictive values apply 
mainly to fibrosis and indicate that a patient with a LSM which indicates fibrosis 
truly does have that level of fibrotic activity. Negative predictive values are more 
often applied to ruling out cirrhosis. This is a value range for LSM which 
accurately indicates that cirrhosis is not present. Another key parameter is LSM 
reliability which correlates to diagnostic accuracy and the predictive values just 
discussed. A liver stiffness evaluation (LSE) is usually considered reliable when it 
fulfills the following criteria: a minimum of ten usable measurements obtained 
with a minimum of a 60% success rate and an interquartile range/median ratio 
(IQR/MR) of less than or equal to 0.30. The last parameter ensures the 
elimination of any measurement which is more than 30% greater or less than the 
median value determined from the ten successful measurements thereby 
excluding extreme outliers which could affect test results.  
 
Boursier et al. published a study in 2013 involving 1,165 patient participants with 
varying disease etiologies in which their aim was to determine whether an 
unreliable LSE according to these standards was any less accurate than a 
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reliable LSE and if there was a need for revision of reliability parameters [3]. This 
was the first study to demonstrate the relevance of the reliability definition. 
Previous studies did indicate that LSE meeting the three established criteria did 
not provide tests with better diagnostic accuracy that those LSE which did not 
meet criteria. In fact, at least 15% of the LSE in clinical settings were excluded 
from analyses after being deemed unreliable when their data may have resulted 
in accurate diagnoses. Researchers evaluated the relevance of the standard 
reliability criteria in order to improve upon them by using diagnostic accuracy as 
the desired outcome. Each patient underwent biopsy and histological diagnosis 
as well as LSE. Out of the 1,165 LSE, 75.7% fulfilled standard reliability criteria. 
Area under receiver operating characteristic curve (AUROC) values for 
significant fibrosis, severe fibrosis, and cirrhosis were not significantly different 
between reliable and unreliable LSE. Researchers found that the number of valid 
measurements and the success rate for obtaining them were not independent 
predictors of discrepancies between histologically-determined fibrotic stage and 
LSE median. However, the parameter which did independently predict 
discrepancies between LSE median and biopsy result was IQR/M, causing 
researchers to conclude that LSE accuracy is a function of increasing intervals of 
IQR/M. LSE medians of 7.1 kPa and 12.5 kPa were used as the diagnostic cut 
offs for significant fibrosis and cirrhosis respectively, or F2 and F4 on the 
METAVIR scale, referencing the Castéra et al study from 2005 [4]. The ultimate 
conclusions drawn by Boursier and colleagues were: 1. the usual definition for 
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LSE reliability was not relevant, 2. reliability depends upon the IQR/M parameter 
and 3. three distinct reliability subgroups are a better way to categorize LSE: very 
reliable, reliable, and poorly reliable (Table 7) [3].  
 
Table 8: LSE reliability categories, adapted from Boursier et al, 2013 [3] 
Reliability IQR/M 
very reliable ≤0.10 
 
reliable 
>0.10 
and 
≤0.30 
poorly reliable >0.30 
 
In their investigation of the reliability of TE, published a year after the Boursier 
study, Pang et al. indicated that the outdated reliability definition for LSE may 
have led to the elimination of 10% of results which could have had a potentially 
significant impact on clinical practice as well as research studies. Using revised 
reliability definitions, approximately two thirds of these unused results would have 
been classified as reliable or very reliable [22]. The researchers conducted a large 
study which took place between July 2008 and June 2011, determining the 
feasibility and reliability of TE with a participant pool of 2,335 patients. Patient 
and operator characteristics were selected to represent a routine clinical practice 
in an effort to determine which properties of both were predictive of poorly 
reliable results. In this study cirrhosis was presumed at a cut off of ≥12.5 kPa and 
the reliability of LSM was divided into three categories based on the Boursier 
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study: very reliable, reliable, and poorly reliable. In the study 29% of 
measurements were very reliable, 66% were reliable, and 4.9% were poorly 
reliable. This was based on the reliability standard of a minimum of ten valid 
measurements with a success rate of ≥60% and an IQR/M≤30%. Poorly reliable 
measurements were defined as having IQR/M≥30% with median liver stiffness ≥ 
7.1 kPa. By standardizing what defined a poorly reliable outcome, researchers 
were able to isolate patient and procedural characteristics which negatively 
impacted LSM reliability, they were as follows: older age, male sex, comorbid 
medical conditions, alcohol abuse, elevated BMI, and higher mean liver stiffness. 
Despite what researchers hypothesized, operator experience was not found to be 
a predictor of poor reliability in LSM [22].  
 
Fibroscan® Limitations  
According to a June 2015 editorial; by Ioan Sporea about the state of liver 
elastography research there are still drawbacks to the method [33]. Limitations are 
related to techniques and equipment as well as patient and technician 
characteristics. The process, which is a nonecho-guided blind method, cannot be 
performed on patients with ascites; it is also influenced by several confounding 
factors such as elevated aminotransferase levels, biliary obstruction, and heart 
failure. The TE machine is also very expensive and must be biannually 
calibrated. Numerous studies have indicated limitations based on patient weight 
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and some probe modifications have been made to counteract these, i.e. the XL 
and S probes.  
 
Necroinflammatory activity flairs, causing increased ALT levels are the main 
confounding factor for an accurate LSM using TE. These acute hepatic flares 
which are common in chronic liver disease result in a higher LSM due to the 
tissue’s response to elevated enzymes. The increased stiffness is not related to 
fibrosis therefore the TE result gives an inaccurate diagnostic picture. Ascites are 
a complication at the end stages of liver disease which result from scarring and 
pressure inside the hepatic vessels causing the accumulation of fluid in the 
peritoneal cavity leading to abdominal swelling. This condition alters LSM 
because the shear wave generated by TE does not propagate through a fluid 
medium. The buildup of fluid in the abdominal cavity of a patient with ascites 
results in a barrier between the probe and the liver. Heart failure results in a 
similar effect on LSM as ascites. The pooling of fluid which is the result of 
congestive heart failure makes obtaining an accurate LSM difficult due to the 
same limitations on shear wave propagation through a liquid medium.  Finally, 
obesity is a predictor of a poorly reliable LSM. Among the 434 patients in the 
Pang et al. study who had available BMI data, poorly reliable scans occurred in 
10% of patients with a BMI≥30kg/m2 compared to 3.1% among non-obese 
patients [22]. Pang et al. determined numerous patient characteristics which lead 
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to decreased reliability of TE in their 2014 study (Table 9) [22]. The most 
prominent effects on LSM reliability were observed for obese patients and those 
with presumed cirrhosis according to the revised reliability standards discussed 
earlier. Disease etiology and comorbidity clearly affect the results of Fibroscan. In 
their 2014 review of the clinical utility of Fibroscan as a diagnostic tool, Wilder 
and Patel included a chart indicating disease type and characteristics of TE for 
identifying cirrhosis among those diseases (Table 10) [39]. The predictive values 
of the LSE varied among the conditions with the most marked reduction in PPV 
among patients with HBV. The test involving patients with HCV-HIV coinfection 
displayed higher PPV and NPV, however, the pKa cut off value for cirrhosis was 
much higher compared to that used for HCV alone. The authors concluded that 
different TE cutoff values should be employed depending on the etiology of liver 
disease and LSM must be cautiously interpreted in the setting of inflammation 
[39]. 
 
Table 9: Independent predictors of poorly reliable Fibroscan examinations, 
Adapted from Pang et al, 2014 [22] 
Variable OR 95% CI 
Age 1.03 1.01-1.05 
Male Sex 1.32 0.87-1.99 
BMI ≥30kg/m2 2.93 0.95-9.05 
Chronic pulmonary disease 1.58 1.05-2.37 
Coagulopathy 2.22 1.31-3.76 
Liver Stiffness 1.03 1.02-1.05 
Cirrhosis 5.24 3.49-7.89 
M Probe vs XL probe 0.64 0.38-1.06 
Operator Experience 0.86 0.67-1.10 
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Table 10: Disease Type and TE Characteristics, taken from Wilder and Patel, 
2014 [39] 
 
Liver 
disease Study # patients 
% METAVIR 
F=4 
Cutoff 
(kPa) Sens Spec PPV NPV AUROC 
HCV Cardoso et al. 363 9% ≥12.5 0.84 0.94 0.58 0.98 0.93 
HBV Cardoso et al. 202 8% ≥11 0.75 0.90 0.39 0.98 0.94 
PBC Corpechot et al. 103 14.5% 16.9 0.93 0.99 0.93 0.99 0.99 
PSC Corpechot et al. 66 14% 14.3 1.00 0.88 0.56 1.00 0.95 
NAFLD Gaia et al. 72 12.5% 10.5 0.78 0.96 0.70 0.97 0.94 
HCV + 
HIV 
Vergara 
et al. 169 15% 14.6 0.91 0.88 0.83 0.94 0.94 
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Table 10: Disease Type and TE Characteristics, taken from Wilder and Patel, 
2014 [39] 
 
 
Additional Applications 
While transient elastography using Fibroscan is not without limitations, there are 
still broad applications for the method, particularly since it is noninvasive. There 
have been numerous studies addressing the utility of TE for the diagnosis and 
monitoring of liver diseases of many etiologies. Although HCV is the primary 
etiology which leads to the development of fibrosis and cirrhosis, there are many 
others such as alcoholic liver disease (ALD), nonalcoholic fatty liver disease 
(NAFLD), chronic hepatitis B infection (HBV), etc. Another critical aspect of 
caring for patients with advanced liver disease is detecting signs of 
decompensation such as biliary atresia or portal hypertension, fibrosis with 
steatosis, and many more. Comorbidities are becoming increasingly relevant 
clinically as well, most prominently with HIV and HCV coinfection. Many studies 
have indicated that LSM is useful, reliable, and accurate in the detection of 
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fibrosis and cirrhosis due to etiologies other than HCV. The method is also suited 
to determine the presence of other complications and characteristics of end 
stage liver disease. 
 
Until recently noninvasive approaches have proven inaccurate in the early 
prediction of clinical decompensation in cirrhotic patients [23]. In their 2011 study 
Robic et al. assessed the accuracy of liver stiffness as a predictor of portal 
hypertension and other related complications in patients with chronic liver 
disease. Portal hypertension (PHT) determines, to a great extent, the prognosis 
of patients with chronic liver disease. The prognostic index for PHT is the hepatic 
venous pressure gradient (HVPG), the determination of which requires an 
invasive hepatic vein catheterization. Additionally, this procedure is not offered in 
all medical settings and is not cost-effective. Several reports which indicated a 
correlation between liver stiffness and HVPG prompted the researchers to 
determine if TE had applications in assessing PHT. One hundred patients 
underwent both invasive HVPG measurement procedures as well as LSM via TE. 
In previous studies the researchers had determined a pKa threshold value of 
21.1 was useful in discriminating between patients with and without significant 
PHT. Using this previously established criteria there was significant correlation 
between LSM values and traditional HVPG which indicated elevated PHT. 
Researchers concluded that LSM is a reliable noninvasive option for both 
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diagnosing clinically significant PHT and informing the treatment course for 
patients with decompensating liver disease [23]. 
The comorbidity of HIV and HCV is becoming increasingly prevalent due to 
progress in highly active anti-retroviral therapies (HAART) which has dramatically 
decreased AIDS-related mortality. Individuals with the HIV infection are living 
longer and liver disease is emerging as a leading cause of morbidity. An 
alternative to biopsy is particularly important for immune-compromised patients 
who are more susceptible to infection and other complications from an invasive 
procedure. Vergara et al. published a study in 2007 discussing the use of TE for 
assessing liver fibrosis in patients with HIV-HCV coinfection to determine if it was 
as reliable as when used to diagnose HCV mono-infected patients [37]. This was a 
cross-sectional study of six tertiary care hospitals and a population169 patients 
was included. The diagnostic performance of previously established LS cut off 
values was evaluated, determining that 20% of patients had been misclassified 
after the comparison of biopsy and LSM data. Diagnostic accuracy of LSM was 
very high for detecting cirrhosis but less so for discriminating between mild and 
moderate fibrosis. According to Vergara et al., their study results were within the 
range of previous reports involving HCV mono-infection. However, TE 
performance was less reliable among HIV-HCV infected patients than HIV-
uninfected patients which fulfilled expectations [37]. Further cutoff value validation 
is needed for TE to be equally reliable in this patient population.  
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CONTINUING RELEVENCE OF LSM 
For over fifty years, biopsy has been the standard to which all other disease 
detection and confirmation methods have been compared. With the 
advancement of several noninvasive methods, particularly in the detection of liver 
disease, biopsy has come under scrutiny for its cost-effectiveness, reliability, and 
safety. Biopsy will never be eliminated as a valuable clinical tool, however, there 
is a case being made for noninvasive procedures to become the primary method 
for both detection and monitoring of hepatic diseases. As the number of 
companies involved in the development of ultrasound-based (US) elastography 
increases, it is likely that liver elastography modules will be included on all or 
most US models in the future which will minimize cost [32]. Additionally, other 
shear wave elastography (SWE) methods are in the process of validation. 
Substantial evidence supports the transition from biopsy to only noninvasive 
methods but it takes time to fully implement new medical standards. Most 
recently, however, a surge in the development of HCV treatments brings the 
continued need for noninvasive disease monitoring into question with treatment 
efficacy at 90% in some cases. 
 
HCV Treatment and Implications 
The hepatitis C virus (HCV) infection remains a significant public health burden 
as the leading cause of liver cirrhosis and hepatocellular cancers with more than 
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170 million individuals infected globally. As this population ages, the risk of 
additional complications is increasing and viral eradication is associated with 
better outcomes. For the last decade, standard HCV treatment based on the 
combination of pegylated-interferon and ribavirin (PR) was limited by sub-optimal 
response rates (54-56%) and significant toxicity [14]. Now that the hepatitis C viral 
lifecycle is well characterized, new treatments which directly interact with 
replication mechanisms have advanced rapidly. Over the last five years, trials 
and clinical implementation of these non-interferon based combination therapies 
called direct-acting antivirals (DAA) are leading HCV treatment in a new direction 
of shorter duration and improved outcomes.  
 
The evolution of DAA therapies radically changes the previous HCV treatment 
paradigm by eliminating the use of interferon as well as creating more universally 
tolerated, highly effective options. An ideal DAA has a high barrier resistance, 
few drug-drug interactions, minimal toxicity, high potency, and a pharmacokinetic 
profile which allows for once daily dosing [14]. Among the growing DAA classes 
are protease inhibitors, polymerase inhibitors, nucleos(t)ide inhibitors, structural 
protein inhibitors, and host-targeting agents all of which have shown varying 
degrees of efficacy. Drugs of this kind have greater specificity and are less likely 
to affect a patient’s immune mechanisms. Patient characteristics which affect 
therapeutic viability are whether the individual is treatment-naïve, the viral load, 
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advanced liver disease, and comorbid conditions. The variables noted lead 
researchers to construct trials which manipulated treatment intervals in an effort 
to study relapse rates and minimum effective durations. While many of these new 
treatments remain in various stages of clinical development, approved DAA’s 
have dramatically improved twelve week success rates up to >90% for most HCV 
genotypes. With continued advancement of DAA’s, reduction in treatment 
duration for therapeutic effect and prohibitive drug costs will need to be 
addressed.  
 
Approved by the FDA in 2014, HARVONI® is a combination of two drugs which 
inhibit viral replication, Ledipasvir and Sofosbuvir. The former is a 
phosphoprotein inhibitor which prevents the assembly and secretion of HCV from 
the host cell, while Sofosbuvir mimics a natural nucleotide and inserts itself into 
the polymerase acting on the RNA primer strand of HCV thus leading to 
replication termination. At a fixed oral dose of 90 mg/400 mg taken once daily 
studies showed varying success based on patient characteristics; i.e. treatment 
naive or experienced, with or without comorbidities, and with our without cirrhosis 
[17]. These characteristics also affected duration of treatment with twelve weeks 
as the least time to achieve viral reduction to within a specified range. In their 
2015 study McQuaid et al. found that less than 2% of their 327 participants 
discontinued treatment due to adverse reactions [20] indicating that HARVONI is 
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well-tolerated. An overall efficacy of 97% was observed in participants with 
genotype 1, meaning those who were treatment naïve and diagnosed with HCV 
but no cirrhosis or comorbid conditions [20]. However, the cost of this treatment is 
prohibitive ranging from $63,000 to $189,000 depending on the duration of 
therapy: eight weeks to twenty-four weeks.  
 
The success of DAA therapy raises a question about the continued relevance of 
improving upon and utilizing noninvasive diagnostic and monitoring methods. 
While an argument exists against the merit of ongoing disease assessment, 
initial diagnoses will always be necessary. Improved treatment methods only 
address existing disease cases, making diagnostic procedures a perpetual need. 
Fibroscan, Fibrotest, and the other methods discussed can only be obsolete 
when there are universal vaccines for viral liver diseases, however, this 
disregards all etiologies which are not viral in nature. Additionally, the cost of 
direct-acting antiviral therapies will make that treatment modality impossible for 
some patients, particularly those in underdeveloped nations whose access and 
resources are already limited. Since the WHO has recognized the public health 
implications of HCV, most evidence supports a growing global disease burden 
requiring comprehensive strategies for treatment and containment. Noninvasive 
diagnostics, transient elastography in particular, remain a viable and necessary 
option for clinical settings worldwide.  
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